Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.72 |
| ▸ | CA2 | P00918 | 8/20 | 0.72 |
| ▸ | ACHE | P22303 | 5/20 | 0.72 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9669811 | 0.94 | CA1 (0.72) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL9505624 | 0.87 | CA1 (0.63) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL20909871 | 0.85 | MTNR1A (0.68) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL7399411 | 0.82 | CA1 (0.64) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL20883597 | 0.81 | MTNR1A (0.62) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL3975748 | 0.81 | MTNR1A (0.90) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL6839556 | 0.81 | CA1 (0.62) | CA1CA2ACHEDRD3DRD2 | |
| SCHEMBL1970411 | 0.81 | MTNR1A (1.00) | CA1CA2MTNR1AMTNR1BDRD2 | |
| SCHEMBL1970413 | 0.81 | MTNR1A (1.00) | CA1CA2MTNR1AMTNR1BDRD2 | |
| SCHEMBL433099 | 0.80 | CA1 (0.70) | CA1CA2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554240-B1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-06 | — | — | EP | disclosed |
| US-7351857-B2 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-01 | — | — | US | disclosed |
| CN-100354259-C | Substituted tetralins and indanes and their use | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | CN | disclosed |
| CN-100349864-C | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA NV (BE) | 2007-11-21 | — | — | CN | disclosed |
| US-20060247314-A1 | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| CN-1798732-A | Substituted tetralins and indanes | JANSSEN PHARMACEUTICA NV (BE) | 2006-07-05 | — | — | CN | disclosed |
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-04 | — | — | US | disclosed |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | US | disclosed |
| CN-1726188-A | Treatment of syndrome X with substituted 1,2,3, 4-tetrahydronaphthalenes and indanes | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-25 | — | — | CN | disclosed |
| CN-1726187-A | Substituted tetralins and indanes and their use | JANSSEN PHARMACEUTICA NV (BE) | 2006-01-25 | — | — | CN | disclosed |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-09-02 | — | — | US | disclosed |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-26 | — | — | US | disclosed |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-19 | — | — | US | disclosed |
| WO-2004037779-A1 | SUBSTITUTED TETRALINS AND INDANES AND THEIR USE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037777-A1 | TREATING SYNDROME X WITH SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037778-A1 | SUBSTITUTED TETRALINS AND INDANES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| EP-0253257-B1 | SUBSTITUTED AMINO-5,6,7,8-TETRAHYDRONAPHTHYL-OXYACETIC ACIDS, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
| US-4921998-A | ANTICOAGULANTS, ANTIISCHEMIC AGENTS, ATHEROSCLEROSIS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-05-01 | — | — | US | disclosed |
| US-4868331-A | ANTICOAGULANTS, ANTIATHEROSCLEROTIC, ANTIISCHEMIC | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| EP-0253257-A2 | Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, method for their preparation and their application as medicaments | BAYER AG (DE) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094786-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | CA1 4769/4885CA2 3706/4885ACHE 4405/4885 |
| US-20060074130-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | CA1 4250/4885CA2 2558/4885ACHE 4010/4885 |
| US-20040171680-A1 | Treating Syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | CA1 4769/4885CA2 3706/4885ACHE 4405/4885 |
| US-20040162352-A1 | Treating syndrome X with substituted tetralins and indanes | PPARG, PPARA, PPARD | CA1 4769/4885CA2 3706/4885ACHE 4405/4885 |
| US-20040167211-A1 | Methods of using substituted tetralins and indanes | PPARA, PPARG, PPARD | CA1 4250/4885CA2 2558/4885ACHE 4010/4885 |
| US-20060247314-A1 | Substituted tetralins and indanes | PPARA, PPARG, PPARD | CA1 4753/4885CA2 3976/4885ACHE 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.